Trust Company of Vermont’s Novo Nordisk NVO Stock Holding History

Trust Company of Vermont’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.32M	Buy	25,899 +288	+1%	+$14.7K	0.06%	182
2025 Q3	$1.42M	Sell	25,611 -924	-3%	-$54.1K	0.06%	166
2025 Q2	$1.83M	Sell	26,535 -155	-0.6%	-$10.5K	0.09%	146
2025 Q1	$1.85M	Sell	26,690 -291	-1%	-$24K	0.09%	141
2024 Q4	$2.32M	Sell	26,981 -1,044	-4%	-$113K	0.11%	127
2024 Q3	$3.34M	Sell	28,025 -582	-2%	-$77.6K	0.17%	108
2024 Q2	$4.08M	Sell	28,607 -532	-2%	-$70.5K	0.22%	98
2024 Q1	$3.74M	Buy	29,139 +11,248	+63%	+$1.34M	0.21%	105
2023 Q4	$1.85M	Sell	17,891 -10,421	-37%	-$1.03M	0.12%	123
2023 Q3	$2.58M	Sell	28,312 -474	-2%	-$41.8K	0.17%	113
2023 Q2	$2.33M	Buy	28,786 +14,700	+104%	+$1.2M	0.15%	129
2023 Q1	$1.12M	Hold	14,086	–	–	0.08%	173
2022 Q4	$953K	Buy	14,086 +64	+0.5%	+$3.75K	0.07%	182
2022 Q3	$699K	Sell	14,022 -428	-3%	-$22.9K	0.06%	187
2022 Q2	$806K	Sell	14,450 -396	-3%	-$22K	0.06%	178
2022 Q1	$825K	Hold	14,846	–	–	0.06%	184
2021 Q4	$832K	Sell	14,846 -254	-2%	-$13.8K	0.05%	187
2021 Q3	$725K	Sell	15,100 -400	-3%	-$19.3K	0.05%	187
2021 Q2	$649K	Sell	15,500 -1,760	-10%	-$68.2K	0.05%	201
2021 Q1	$582K	Sell	17,260 -150	-0.9%	-$5.34K	0.04%	205
2020 Q4	$608K	Sell	17,410 -306	-2%	-$10.6K	0.05%	189
2020 Q3	$615K	Sell	17,716 -140	-0.8%	-$4.67K	0.06%	182
2020 Q2	$585K	Sell	17,856 -1,500	-8%	-$47.9K	0.06%	179
2020 Q1	$583K	Sell	19,356 -110	-0.6%	-$3.27K	0.05%	191
2019 Q4	$563K	Sell	19,466 -1,300	-6%	-$36K	0.04%	210
2019 Q3	$537K	Sell	20,766 -1,220	-6%	-$30.9K	0.04%	219
2019 Q2	$561K	Sell	21,986 -1,900	-8%	-$47K	0.05%	213
2019 Q1	$625K	Sell	23,886 -2,410	-9%	-$59.2K	0.05%	200
2018 Q4	$606K	Sell	26,296 -2,300	-8%	-$51.1K	0.06%	199
2018 Q3	$674K	Sell	28,596 -4,290	-13%	-$105K	0.06%	202
2018 Q2	$758K	Sell	32,886 -1,432	-4%	-$34K	0.07%	191
2018 Q1	$845K	Sell	34,318 -11,230	-25%	-$295K	0.08%	174
2017 Q4	$1.22M	Sell	45,548 -3,350	-7%	-$85.2K	0.11%	159
2017 Q3	$1.18M	Sell	48,898 -4,542	-8%	-$103K	0.12%	158
2017 Q2	$1.15M	Sell	53,440 -9,508	-15%	-$192K	0.12%	153
2017 Q1	$1.08M	Sell	62,948 -15,420	-20%	-$268K	0.12%	150
2016 Q4	$1.41M	Sell	78,368 -14,054	-15%	-$255K	0.16%	127
2016 Q3	$1.92M	Sell	92,422 -7,506	-8%	-$186K	0.24%	108
2016 Q2	$2.69M	Buy	99,928 +30	+0%	+$823	0.36%	89
2016 Q1	$2.71M	Buy	99,898 +820	+0.8%	+$22K	0.38%	86
2015 Q4	$2.88M	Buy	99,078 +2,360	+2%	+$65.3K	0.41%	80
2015 Q3	$2.62M	Sell	96,718 -1,622	-2%	-$45.9K	0.41%	80
2015 Q2	$2.69M	Sell	98,340 -330	-0.3%	-$9.28K	0.39%	84
2015 Q1	$2.63M	Sell	98,670 -1,976	-2%	-$45.5K	0.38%	82
2014 Q4	$2.13M	Sell	100,646 -408	-0.4%	-$9.11K	0.31%	95
2014 Q3	$2.41M	Buy	101,054 +1,292	+1%	+$29.7K	0.36%	84
2014 Q2	$2.3M	Buy	99,762 +9,090	+10%	+$201K	0.36%	83
2014 Q1	$2.07M	Buy	90,672 +5,732	+7%	+$122K	0.34%	86
2013 Q4	$1.57M	Buy	84,940 +31,060	+58%	+$541K	0.26%	102
2013 Q3	$912K	Buy	53,880 +4,170	+8%	+$70.1K	0.17%	128
2013 Q2	$770K	Buy	+49,710	New	+$827K	0.15%	127

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Trust Company of Vermont's NVO Position: Q4 2025 in Review

Trust Company of Vermont increased its Novo Nordisk (NVO) stake by 1.1% in Q4 2025, buying an estimated $14.7K and bringing the position to 25,899 shares worth $1.32M. The position accounts for 0.06% of the portfolio, ranked #182.

Trust Company of Vermont first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.08M in Q2 2024. 1,415 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Trust Company of Vermont held 25,899 shares of Novo Nordisk worth $1.32M as of Q4 2025.
Trust Company of Vermont bought 288 Novo Nordisk shares in Q4 2025, an estimated $14.7K.
Novo Nordisk made up 0.06% of Trust Company of Vermont's portfolio in Q4 2025, its #182 holding.
Trust Company of Vermont first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
Trust Company of Vermont's Novo Nordisk position peaked at $4.08M in Q2 2024.
1,415 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.